Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors

@inproceedings{MacTavish2010EnhancementOV,
  title={Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors},
  author={Heather MacTavish and Jean-Simon Diallo and Baocheng Huang and Marianne M Stanford and Fabrice Le Boeuf and Naomi De Silva and Julie Cox and John Graydon Simmons and Tanya Guimond and Theresa Falls and J Andrea Mccart and Harry L. Atkins and Caroline J. Breitbach and David H. Kirn and Steve Thorne and John Cameron Bell},
  booktitle={PloS one},
  year={2010}
}
Histone deacetylase inhibitors (HDI) dampen cellular innate immune response by decreasing interferon production and have been shown to increase the growth of vesicular stomatitis virus and HSV. As attenuated tumour-selective oncolytic vaccinia viruses (VV) are already undergoing clinical evaluation, the goal of this study is to determine whether HDI can also enhance the potency of these poxviruses in infection-resistant cancer cell lines. Multiple HDIs were tested and Trichostatin A (TSA) was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS, ESTIMATED 36% COVERAGE

92 Citations

01020'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 92 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

  • R. W. Johnstone
  • Nat. Rev. Drug Discov
  • 2002
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…